Summary Verapamil had previously been shown to increase cellular melphalan uptake and cytotoxicity in fibrosarcomas, and increased the area under the blood concentration versus time curve (AUC) for melphalan in CBA mice. Verapamil (10mgkg-1 i.p.) had no effect on the fractional distribution of cardiac output (FDCO), measured with 86Rb-rubidium chloride, to subcutaneous fibrosarcomas. 14C-Melphalan uptake by FS13 fibrosarcomas was increased 60 min after verapamil (10mg kg1 i.p.), but not after lower doses which did not affect the AUC. Flunarizine (5mg kg-I i.p.) also had no effect on FDCO to FS13 fibrosarcomas, and tended to increase 14C-melphalan content of blood and the fibrosarcomas and to promote growth delay by melphalan. Alcohol increased FDCO to FS13 fibrosarcomas, maximally at a 1:20 dilution in saline, but had no effect on 14C-melphalan uptake or growth delay. Thus, melphalan cytotoxicity correlated with tumour melphalan uptake, and both followed changes in the AUC for melphalan but not changes in FDCO. In these murine fibrosarcomas melphalan uptake and cytotoxicity were not limited by blood flow.
The response rate to melphalan has been increased by the administration of high intravenous doses with autologous bone marrow rescue and priming (Hedley et al., 1978; McElwain et al., 1979; Cornbleet et al., 1983) . However, further dose escalation is limited by gastrointestinal toxicity (Millar et al., 1978b, c) and other ways of increasing the antitumour effect are being sought. Delivery of most cytotoxic agents to tumours is thought to be at least partly flow-limited and hence able to be increased by increasing blood flow (Nugent & Jain, 1984) . The calcium antagonists, verapamil and flunarizine, increased the blood flow to rat mammary carcinomas, measured using radiolabelled microspheres (Kaelin et al., 1982; . These agents decreased vascular resistance more in the tumour than in the host vessels, so that so long as blood pressure was maintained, tumour blood flow was enhanced. However, inhibition of platelet aggregation (Honn et al., 1985; Tsuruo et al., 1985) , and inhibition of hypoxia-induced vasoconstriction and reduced red cell deformability (Van Nueten & Vanhoutte, 1981) , were thought to play a part (Kaelin et al., 1982; . Effects on tumour drug uptake or cytotoxicity were not studied.
Verapamil enhanced the cytotoxicity of melphalan to two subcutaneous murine fibrosarcomas , due both to an affect on melphalan pharmacokinetics in mice and to enhancement of cellular melphalan uptake. The evidence that the effect of verapamil was not due to increased blood flow to the fibrosarcomas is now presented, along with the results in subcutaneous human melanoma HX46 xenografts. Furthermore, the effects of verapamil on in vivo 14C-melphalan uptake by the fibrosarcomas and xenografts were studied, and related to growth delay. The effects of flunarizine were compared with those of verapamil in the fibrosarcomas. The human melanoma HX46 xenograft was implanted as 1-2mm pieces subcutaneously in male CBA mice, immunosuppressed by thymectomy and 9 Gy total body irradiation from a 60Co-cobalt source, preceded 48 h by cytosine arabinoside 200mgkg-1 by i.p. injection (Millar et al., 1978a; Steel et al., 1978) . Passages 5-7 were used, 3 weeks after implantation, a human karyotype demonstrated through passage 7 (Selby et al., 1980 which contained ethanol 39.5mgml-1, mannitol 45mgml-1 and lactic acid 3.2 mg ml-1, in the presence or absence of flunarizine 1 mg ml-1, were diluted in saline 1: 1 and protected from light.
Uptake of 86Rb-rubidium chloride The fractional distribution of cardiac output (FDCO) to tumours and tissues in CBA mice was determined using 86Rb-rubidium chloride, in a method adapted from Sapirstein (1958) and Zanelli & Fowler (1974) . Unanaesthetised mice were given 86Rb, a weighed dose of 3-5pCi in 0.1ml saline, i.v. through the tail vein, flushed with 0.1 ml saline, and were killed 60sec later with 0.2ml saturated potassium chloride i.v. The mice were exsanguinated from the neck to standardise residual blood; tumours, liver, heart, kidneys, proximal small intestine (jejunum), quadriceps muscles, femurs and a segment of skin excised and weighed. These tissues, tail, i.v. needle and tubing were counted in double-walled glass tubes, with weighed dose standards, for 10 min in a gamma-counter (Kontron). Counts in the tail and tubing were subtracted from the dose to correct for extravasation. Mice with more than 20% 86Rb dose in the tail, and tumours weighing <40 mg were excluded. The FDCO, as % dose g 1 wet tissue was expressed as mean+s.e. for groups of at least 5 mice, and of at least 10 tumours, and compared by Student's t test. Treated and control mice were studied alternately to allow for possible circadian variations.
Uptake of 14C-melphalan Groups of at least 5 tumour-bearing mice were treated with 14C-melphalan, usually 10mg kg-1 i.p., with verapamil or saline i.p., and killed up to 4 h later. The mice were bled from the neck under ether anaesthesia, and the tumours and jejunum excised and weighed. The 14C content of blood (l00p1) and tissues was determined using a Packard Oxidiser 306 (United Technologies Packard); 14C was trapped in 9-10 ml Carbosorb, added to 13 ml Permafluor V (Packard) and counted with dose standards in a liquid scintillation counter (Intertechnique). 14C-melphalan was expressed as % dose or pg ml-l blood or g1 wet tissue, and means + s.e. compared by t test.
Tumour growth delay Mice were divided into treatment and control groups of at least 5 mice with bilateral tumours. 
Results
Uptake of 8 6Rb by fibrosarcomas The 86Rb content of FS12 and FS13 fibrosarcomas, and of heart, kidney, jejunum, liver, muscle, skin and femur in unanaesthetised CBA mice, was constant from 15 to 90sec after 86Rb administration (Robinson, 1985) , as required for validity of the method (Sapirstein, 1958) . The FDCO to the fibrosarcomas decreased with increase in weight, as demonstrated for FS13 in Figure 1 , which shows the data as mean values for control tumours from 24 experiments. The correlation coefficient for weight and 86Rb uptake of individual FS13 fibrosarcomas was r = -0.5272, P < 0.001 (n = 269), and for FS12 fibrosarcomas, r= -0.4283, P<0.002 (n = 59). Intravenous or i.p. administration of a volume of saline equivalent to that of a vasoactive agent did not itself affect the FDCO (Robinson, 1985 Table I ). The increase in FDCO to the FS13 fibrosarcomas was dose-related and was greatest 20min after i.p. administration of aa 1:20, an increase also occurring after aa 1:10 (Table I ). In contrast, alcohol had no effect on the FDCO to the human melanoma HX46 xenografts, aa 1:20 lOmlkg-1 resulting in 86Rb uptake of 2.08 +0.26% doseg-1 (n= 11) compared with 1.82+0.21
(n= 10) in controls.
Effect of alcohol on tumour '4C-melphalan uptake and growth delay Uptake of 14C-melphalan by FS13 fibrosarcomas was determined 60min after i.p. administration in (Table II) . There was a small decrease in blood 14C-melphalan after aa 1:50 of doubtful significance, but no differences in tumour "4C-melphalan uptake.
The solvent had no effect on growth delay of the FS13 fibrosarcomas; melphalan 7mgkg-1 i. , with peak blood levels at 30 min, and significantly greater levels after verapamil from 15min for at least 2 h. The dose of verapamil which had no effect on the AUC, 2.5mg kg-' i.p. , had no effect on '4C-melphalan content of FS13 fibrosarcomas although there was a small effect on blood 14C-melphalan at 60min in this experiment (Table III) . The increase in tumour 14C-melphalan after verapamil 10 mg kg-1 i.p. was confirmed in this experiment. Verapamil 2.5mg kg-' i.v., which reduced FDCO to FS13 fibrosarcomas, had no effect on`C- (Table III) . In a separate experiment, verapamil 2.5mg kg-i.v. had had no effect on the AUC for "4C-melphalan administered i.p. (Robinson, 1985) . The human melanoma HX46 xenografts showed no change in '4C-melphalan content with verapamil 10mg kg-' i.p., at 60 min (Table III) , but a significant increase in blood 14C-melphalan did not occur. It is possible that the effects of verapamil on melphalan pharmacokinetics were somehow modified in these irradiated mice.
Effect offlunarizine on tumour FDCO and "4C-melphalan uptake Flunarizine, another calcium antagonist and vasodilator, had no significant effect on the FDCO to FS13 fibrosarcomas when 5mgkg-1 were given i.p. (Table IV) . Placebo, providing the equivalent of aa 1:50, lOmlkg-1 i.p., also had no effect on FDCO, but tumour blood flow was significantly lower after flunarizine than placebo. Flunarizine and placebo had no significant effects on FDCO to normal tissues except for a small increase in FDCO to muscle after flunarizine. Mice with FS13 fibrosarcomas were treated with '4C-melphalan 5 mg kg-1 i.p. with aa 1:50 solvent, with either saline, placebo or flunarizine 5mg kg-1 i.p. (Table IV) . (Mice treated with placebo or flunarizine received twice the dose of ethanol compared with controls, total just less than aa l:20, but this should not affect the result because tumour 14C-melphalan was the same for aa 1:50 and aa 1:20 (Table II) .) Sixty minutes after flunarizine, blood 14C-melphalan was increased compared with placebo treatment but not compared with saline, and the increase in tumour 14C-melphalan was not significant (Table IV) .
Effect of verapamil and flunarizine on growth delay by melphalan Verapamil 10mg kg-1 i.p. promoted the growth delay by melphalan for FS12 and FS13 fibrosarcomas, with a greater effect in FS12, the less sensitive tumour . Verapamil 2.5 mgkg -i.p., which had no effect on AUC or tumour uptake of melphalan, had no modifying effect on growth delay of FS13 fibrosarcomas by melphalan (Table V) . Verapamil 10mgkg-1 i.p. enhanced growth delay in the HX46 xenografts, but to a smaller extent than in the fibrosarcomas. Verapamil 10mgkg-1 i.p. alone had no effect on the growth of either the fibrosarcomas or the HX46 xenografts. Flunarizine had a small enhancing effect on growth delay in the fibrosarcomas (Table V) .
Discussion
Verapamil 10mg kg-1 i.p. had no effect on the relative blood flow (FDCO, measured with 86Rb) to subcutaneous murine fibrosarcomas, and increased 14C-melphalan uptake 60min after administration, previous work having shown verapamil to potentiate growth delay by melphalan in these fibrosarcomas and to increase the AUC of melphalan . Verapamil 2.5 mg kg-1 i.p., which had not affected the AUC , had no effect on tumour melphalan uptake nor cytotoxicity. Verapamil 2.5mgkg-1 i.v., equivalent to about 15-20mgkg-1 i.p. because of first pass hepatic metabolism (Stone et al., 1980) , decreased FDCO to the fibrosarcomas but had no effect on either tumour uptake or the AUC of melphalan. The effects of flunarizine resembled those of verapamil on fibrosarcoma FDCO, melphalan uptake and growth delay, but were less marked. Alcohol increased the FDCO to the fibrosarcomas, but when administered as melphalan solvent, had no effect on melphalan uptake and cytotoxicity, nor on the AUC. For melphalan, changes in cytotoxicity followed changes in tumour uptake, and reflected changes in the AUC but not in tumour blood flow. The subcutaneous human melanoma HX46 xenografts differed from the fibrosarcomas in showing no increase in 14C-melphalan content after verapamil 10mgkg-1 i.p., but no increase in AUC occurred and verapamil enhanced the growth delay of HX46 by melphalan in a different experiment. The xenografts showed no change in FDCO after verapamil, but in contrast to the fibrosarcomas, FDCO did not increase after the acid alcohol solvent. The latter finding suggests a difference in vascular supply, possibly intrinsic to the xenografts or resulting from total body irradiation prior to implantation (Clifton & Jirtle, 1975) .
Verapamil potentiation of cellular melphalan uptake by the fibrosarcomas, described previously , probably contributed to the enhanced in vivo melphalan uptake and cytotoxicity, because of the correlation between enhanced cellular uptake and growth delay for FS12 and FS13 . The lack of a fall in tumour 14C-melphalan despite the decrease in FDCO to fibrosarcomas, without any change in AUC, after verapamil 2.5mg kg-1 i.v., might be explained by enhanced cellular melphalan uptake, or by the absence of limitation of melphalan uptake by blood flow. The small potentiation of growth delay in HX46 might be due to an effect on the AUC of melphalan, which was not significant in the experiment in Table III , or perhaps due to an effect on cellular melphalan uptake. Unfortunately it was not possible to measure the effect of verapamil on melphalan uptake by HX46 cells in vitro . However if the AUC was unaffected, as in Table III , enhanced cellular melphalan uptake might have occurred.
Although melphalan was measured as 14C-melphalan, total 14C-melphalan correlated with parent melphalan and with 14C-melphalan bound to cellular macromolecules including DNA in other tumours Furner & Brown, 1980) , and verapamil had no effect on melphalan hydrolysis . The vascular volume of the fibrosarcomas was 1.4% (14 l g-1), determined using 59Fe-labelled red cells (Robinson, 1985) , making it unlikely that changes in tumour 14C-melphalan content were due to changes in the 14C-melphalan concentration of blood within the tumour. In mice, verapamil might affect melphalan pharmacokinetics by increasing absorption or retarding renal clearance, through enhanced jejunum and decreased renal blood flow (see Figure 2 ). In man, oral verapamil increased renal, hepatic and splanchnic flow, after the first dose (Meredith et al., 1985) , and little net effect on melphalan pharmacokinetics might be expected, depending on the relative contributions of these organs. Verapamil 10mgkg-1 i.p. in mice both had cardiovascular effects and increased tumour melphalan uptake, perhaps suggesting potential for similar tumour effects at safe cardiovascular doses in man.
Alcohol was the only vasodilator to increase blood flow to the fibrosarcomas; verapamil, flunarizine, epoprostenol and phentolamine failed (Robinson, 1985) . Most other vasodilators also did not increase blood flow to experimental tumours, including phenoxybenzamine, isoprenaline, papaverine and hydralazine (Jirtle et al., 1978; Debreczeni et al., 1980; Mattsson et al., 1982; Chan et al., 1984) . Tumour perfusion depends on the relative vascular resistance of the tumour and host circulations and on systemic blood pressure (Chan et al., 1984; Suzuki et al., 1984) . Only doses of verapamil and flunarizine which reduced tumour vascular resistance without reducing blood pressure increased tumour blood flow (Kaelin et al., 1982; and the associated change in tumour FDCO would have been detectable by 86Rb. Discrepancies have been reported in the FDCO derived from the distribution of microspheres, used by Kaelin et al. (1982; , and of 86Rb in unanaesthetised rats (Foster & Frydman, 1978) . These arise from the anatomical and functional differences of various capillary beds (Mendell and Hollenberg, 1971) which make the assumption (Sapirstein, 1958) that every tissue has the same extraction ratio for 86Rb not strictly true (Appelgren, 1979) . In mice, microspheres cannot be used and 86Rb is accepted as a valid indicator of capillary flow (Zanelli & Fowler, 1974; Zanelli et al., 1975; Wetterlin et al., 1977; Appelgren, 1979) . However, inability to measure cardiac output and blood pressure in mice makes adjustment of vasodilator dose difficult.
Tumour melphalan uptake was not limited by blood flow, with no increase in uptake when FDCO was increased by alcohol. The 14C-melphalan content of FS13 fibrosarcomas at 60min increased with tumour weight (Robinson, 1985) , in contrast to the decrease in FDCO, suggesting that with time melphalan reached even poorly perfused regions. This is supported by 1 4C-melphalan autoradiography, which showed radioactivity throughout histologically viable and necrotic regions of FS13 fibrosarcomas after 1 h (Robinson, 1985) . Distribution of 14C-misonidazole was limited by flow only in very poorly perfused parts of subcutaneous sarcomas in rats (Blasberg et al., 1985) . Thus, for these experimental tumours, blood flow does not limit melphalan uptake, but agents such as verapamil which increase cellular melphalan transport increase cytotoxicity. However, for tumours with very low blood flow, as is the case in many human tumours where flows as low as 1/30 that of surrounding normal tissue have been recorded (Shibata & MacLean, 1966) , or for cytotoxic drugs cleared more rapidly from the blood than melphalan, drug uptake may be limited by blood flow and be increased by vasoactive agents such as alcohol, or angiotensin II (Robinson, 1985) . The equivalent dose of ethanol to humans receiving high-dose melphalan i.v. would be less than I of that in mice given aa 1:20 i.v., and could safely be increased in man if ethanol was found to increase blood flow to some human tumours (of which xenografts in irradiated mice may not be representative) and if drug uptake by them was flow-limited.
It was concluded that in the subcutaneous murine fibrosarcomas and human melanoma HX46 xenografts, tumour melphalan uptake was not limited by blood flow, and that cytotoxicity correlated with tumour melphalan uptake, both changing with the AUC for melphalan and with verapamil enhancement of cellular melphalan uptake.
